Partnerships AbbVie: US co-development/commercialization collaboration (Ironwood records its share of LINZESS net profit/loss); ex-US partners market as LINZESS/CONSTELLA
Indications
irritable bowel syndrome with constipation (IBS-C)(Approved)
chronic idiopathic constipation (CIC)(Approved)
Status note Linaclotide; first FDA-approved GC-C agonist class. Majority of company revenue from US LINZESS sales; pediatric linaclotide programs referenced but undescribed.
Apraglutide
Phase 3 · ActiveModality: synthetic peptide analog (long-acting)
Target GLP-2
Partnerships VectivBio (acquired): origin; Asahi Kasei Therapeutics (AKTX): exclusive license for apraglutide in Japan (2022)
Indications
short bowel syndrome with intestinal failure (SBS-IF)(Phase 3)
Status note Next-generation long-acting synthetic peptide analog of GLP-2 for SBS patients dependent on parenteral support; confirmatory Phase 3 trial recruiting.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.